« Previous Next » The Journal of Allergy and Clinical Immunology
Volume 124, Issue 5 , Pages 895-902.e4 , November 2009

Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study

Tmirah Haselkorn, PhD
- Genentech, Inc, South San Francisco, Calif
- Reprint requests: Tmirah Haselkorn, PhD, Genentech, Inc, 1 DNA Way, MS 58B, South San Francisco, CA 94080.
James E. Fish, MD
- Genentech, Inc, South San Francisco, Calif
Robert S. Zeiger, MD, PhD
- Department of Allergy, Kaiser Permanente Southern California, San Diego, Calif
Stanley J. Szefler, MD
- Department of Pediatrics, National Jewish Health, Denver, Colo
Dave P. Miller
- ICON Clinical Research, San Francisco, Calif
Bradley E. Chipps, MD
- Capital Allergy and Respiratory Disease Center, Sacramento, Calif
F. Estelle R. Simons, MD
- University of Manitoba, Winnipeg, Manitoba, Canada
Scott T. Weiss, MD, MS
- Channing Laboratory, Harvard Medical School, Boston, Mass
Sally E. Wenzel, MD
- University of Pittsburgh Asthma Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pa
Larry Borish, MD
- University of Virginia Health Systems, Charlottesville, Va
Eugene R. Bleecker, MD
- Wake Forest University Health Sciences, Winston-Salem, NC
TENOR Study Group
- For a complete list of TENOR Study Group members, please contact Genentech, Inc.

Received 23 December 2008 ,Revised 6 July 2009 ,Accepted 24 July 2009.

Study population. Two hundred sixty-seven of 1074 patients whose pattern of asthma control was VPC-VPC-(N)WC or VPC-N(WC)-VPC were excluded. ^∗Asthma control assessments at baseline, month 12, and mont

Study population. Two hundred sixty-seven of 1074 patients whose pattern of asthma control was VPC-VPC-(N)WC or VPC-N(WC)-VPC were excluded. ^∗Asthma control assessments at baseline, month 12, and month 24.
- Full-Size Image
- Download to PowerPoint
Risk of asthma exacerbations at the month 30 visit associated with consistently VPC asthma as defined by impairment domain of the NHLBI guidelines. Final adjusted models for hospitalization and ED vis

Risk of asthma exacerbations at the month 30 visit associated with consistently VPC asthma as defined by impairment domain of the NHLBI guidelines. Final adjusted models for hospitalization and ED visits include prior hospitalizations or ED visits, number of long-term controllers, body mass index, allergic triggers, nonallergic triggers, percent predicted forced vital capacity, race/ethnicity, and age. Final adjusted models for corticosteroid bursts include prior corticosteroid burst, chronic obstructive pulmonary disease, nonallergic triggers, percent predicted FEV₁/forced vital capacity ratio, race/ethnicity, and age.
- Full-Size Image
- Download to PowerPoint
Demographic and clinical factors predictive of consistently VPC asthma as defined by the impairment domain of the NHLBI guidelines. ∗Allergic triggers considered were pollen, animal dander, dust, and

Demographic and clinical factors predictive of consistently VPC asthma as defined by the impairment domain of the NHLBI guidelines. ^∗Allergic triggers considered were pollen, animal dander, dust, and mold. ^∗∗Predictive factors that were statistically significantly associated with consistently poorly controlled asthma are shown.
- Full-Size Image
- Download to PowerPoint

Supported by Genentech, Inc, and Novartis Pharmaceuticals Corporation.

Disclosure of potential conflict of interest: J. E. Fish is an employee of Genentech. R. S. Zeiger is a consultant for Aerocrine, AstraZeneca, Genentech, GlaxoSmithKline, Merck, Novartis, and Schering and has received research support from Aerocrine, Sanofi-Aventis, Genentech, Merck & Co, and GlaxoSmithKline. S. J. Szefler is a consultant for GlaxoSmithKline, Genentech, and Merck and has received research support from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (NHLBI) Childhood Asthma Management Program (CAMP), NHLBI Childhood Asthma Research and Education, the NIH/NHLBI Asthma Clinical Research Network, the NIH/National Institute of Allergy and Infectious Diseases Inner City Asthma Consortium, Roos Pharmaceuticals, and GlaxoSmithKline. D. P. Miller is employed by ICON Clinical Research, which received research funding from Genentech. B. E. Chipps has received research support from Genentech, Alcon, and AstraZeneca; has provided expert witness testimony for AstraZeneca regarding Symbicort research; and is a consultant on the speakers' bureau for Sepracor, GlaxoSmithKline, AstraZeneca, Alcon, Genentech, Novartis, Schering-Plough, Aventis, MADA. F. E. R. Simons has received research support from the Canadian Institutes of Health Research. S. T. Weiss is a consultant for Genentech. S. E. Wenzel has received research support from GlaxoSmithKline and is an advisory board member for the Global Initiative for Asthma. L. Borish is a consultant for Genentech, is on the speakers' bureau for Merck, and has received research support from GlaxoSmithKline. E. R. Bleecker is a consultant for AstraZeneca, Boehringer-Ingelheim, Centocor, Genentech, GlaxoSmithKline, Novartis, Pfizer, Wyeth, and Merck and has received research support through Wake Forest University Health Sciences, Aerovance, Amgen, AstraZeneca, Boehringer-Ingelheim, Centocor, Ception, Genentech, GlaxoSmithKline, Novartis, Novartis, Pfizer, and Wyeth. T. Haselkorn has been a paid consultant to Genentech since December 2002.

PII: S0091-6749(09)01144-0

doi: 10.1016/j.jaci.2009.07.035

« Previous Next » The Journal of Allergy and Clinical Immunology
Volume 124, Issue 5 , Pages 895-902.e4 , November 2009